Filing step-change
GLPL · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-20 · Evidence medium
GlaxoSmithKline India (GLPL) closed at 32 INR, a decline of 0.013 INR, after a strong quarterly performance with its gross margin accelerating to 64.04%, up from 29.13%.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 64.04 % | 29.13 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 29.13 % | 13.2 | ▲ |
Cite this
Source: Samhati filing step-change for GLPL (2026-10). Observation: GlaxoSmithKline India (GLPL) closed at 32 INR, a decline of 0.013 INR, after a strong quarterly performance with its gross margin accelerating to 64.04%, up from 29.13%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/glpl/q/2026-10
Other periods